Chongqing Zhifei Biological Products stock
300122.SZSHZChongqing Zhifei Biological Products Co., Ltd., HealthcareISIN CNE100000V20
35Score 35 out of 100, Weak
Price and trend
62 / 100
Price history
−36% in one yearThe chart shows daily closes over 16 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 3.3% below it.
Since March 2024 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 63).
The price is 36% below its 52-week high. Largest decline in 16 years: 92% (April 2021 to July 2026).
Chart figures for advanced users
- SMA 50$2.00
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$2.15
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)63
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$1.71
- The lowest closing price of the last twelve months.
- Resistance$3.26
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- In fiscal 2025 it reported revenue of $1.34B (down 65.6% year on year) and a loss of $2.21B.
- MEQIRI Score 35 out of 100 (Weak): rank 602 of 703 in Healthcare, median 53.
Strengths
None of our strength checks applies.
Weaknesses
- Margin fallingOperating margin −194.9%, average of the prior years 22.9% (to 2024).Profitability 12
- DilutionShare count up 50% since 2020.Capital allocation 9
- Loss-makingLoss of $2.13B over the last 12 months.Fundamentals 52
The score is held back by profitability and capital allocation.
computed just now
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
not measuredA fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at less than a quarter of the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 27.9% on the twelve months before. Revenue has grown strongly since 2007, at around 17% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross −144%, operating −195%, net −164%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 27 Apr 2027in 165 days
- Last reported
- 26 Oct 2026EPS reported $0.01 (expected $0.01)in line with expectations
Analyst estimates
Earnings estimates have barely changed since 8 Nov 2026.
- Earnings per share
- −$0.070.0%
- Revenue
- $1.15B0.0%
- Earnings per share
- −$0.040.0%
- Revenue
- $1.46B0.0%
MEQIRI has stored the estimates since 8 Nov 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Chongqing Zhifei Biological Products
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
703 rated companies in Healthcare
- This company
- 35
- Sector median
- 53
Categories against the sector medianMedian of 703 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
ETFs that hold Chongqing Zhifei Biological Products
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| HSBC MSCI China A UCITS ETF USDH41K | 0.12% | 0.30% | €68.31M |
| Xtrackers Harvest CSI300 UCITS ETF 1DRQFI | 0.09% | 0.65% | €251.68M |
| Xtrackers Harvest CSI A500 UCITS ETF 1DAH50 | 0.07% | 0.65% | €10.81M |
Show 5 more
| Franklin FTSE China UCITS ETFFLXC | 0.02% | 0.19% | €1.43B |
| Vanguard FTSE Emerging Markets UCITS ETF (USD) AccumulatingVFEA | 0.00% | 0.17% | €5.24B |
| iShares Growth Portfolio UCITS ETFMAGR | 0.00% | 0.25% | €111.75M |
| Amundi Prime All Country World UCITS ETF AccWEBN | 0.00% | 0.07% | €8.95B |
| iShares Conservative Portfolio UCITS ETFMACV | 0.00% | 0.25% | €16.6M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 2 May 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.